World Immuno-oncology Market Outlook and Key Players 2026

Potential of immuno-oncology therapies to selectively identify and attack the cancer cells which reduces the side effects is intended to take the global market for immuno-oncology to a new high in the coming future. Immuno-oncology therapies target the immune system of the body and not the tumor, by activating immune system to recognize the cancer cell and kill them by natural mechanism. These immuno-oncology therapies are becoming choice of therapy by oncologists as they provide long lasting effects such that the body can adapt to the changing behavior (resistance) of cancer cells toward immune system and improve the quality survival. Commercial immuno-oncology therapies are available against cancer types such as prostate cancer and melanoma and many other are under clinical studies. Some of the available immuno-oncology therapies include Zaltrap, Keytruda, Opdivo, Yervoy, Imlygic, Zyclara and others. Cancer treatment vaccines are currently being developed which can enhance the immune system’s response to tumor cell. Some of the FDA approved cancer treatment vaccines include Sipuleucel-T, bacillus Calmette-Guérin (BCG) etc.

Global Immuno-oncology Market: Drivers and Restraints

Effective mechanism of immuno-oncology therapies for the patient with poor prognosis is expected to drive the growth of immuno-oncology market. The evidences from clinical trials reveals that the effects of immuno-oncology therapies on cancer cells would last for a longer time by preparing the immune system to fight against cancer cells even after the reduction in tumor cells. Additionally the side-effects associated with immuno-oncology therapies are limited as compared to many other cancer therapies, which creates a positive impact on the growth of immuno-oncology market. The restraining factors for the immuno-oncology therapies market are high cost of treatment, lack of awareness and slower pipeline development

Request Sample

Global Immuno-oncology Market: Segmentation

The global immuno-oncology market has been classified on the basis of product type, end user and geography.

Based on product type, the global immuno-oncology market is segmented as follows:

  • Monoclonal Antibodies (mAb)
  • Antibody Drug Conjugates
  • Cancer Treatment Vaccines
  • Chimeric Antigen Receptor (CAR) T-Cell Therapies
  • Interferon and Cytokine therapies
  • PD-1/PD-L1 inhibitors
  • Others

Based on end user, the global global immuno-oncology market is segmented as follows:

  • Hospitals
  • Clinics
  • Cancer Research Centers and Institutes

Global Immuno-oncology Market: Overview

Extensive scope of immuno-oncology agents in various cancer treatments would provide maximum share to immuno-oncology treatment in overall cancer drug market during the forecast period. This lucrative opportunities in immuno-oncology treatment would provide boost to the product development during the forecast period. The slower pace of research and development activities and capital intense investment in manufacturing are the factors extending the commercialization of immuno-oncology therapies. However, lesser side effects associated with immunological treatments and better efficacy is expecting to get positive response from the cancer specialists after commercialization of immuno-oncology therapies.

Global Immuno-oncology Market: Region-wise Outlook

Geographically, the global Immuno-oncology therapies market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America and Europe are the lucrative regions for immuno-oncology market due to their potential to invest the huge amount of money in the development of immuno-oncology therapies and availability of better reimbursement policies. Moreover, affordability for the cost of treatment is also high in North America and Europe. The global immuno-oncology market is expected to grow during the forecast period due to increasing investment by multinational companies in the cancer research

For more info (desk of content material), Figures and Tables of the report @

Global Immuno-oncology Market: Key Players

Some of the key players in global immuno-oncology market are Seattle Genetics, Inc., Genentech, Inc., F. Hoffmann-La Roche Ltd., Eisai Co. Ltd., Amgen Inc., Bayer AG, Sanofi Aventis LLC., Merck & Co., Inc., Bristol-Myers Squibb Company, Dendreon Corporation and others. The global immuno-oncology market is expected to grow during the forecast period due to increasing investment by multinational companies in the cancer research.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s